FTSV Forty Seven Inc.

12.54
+0.25  (+2%)
Previous Close 12.29
Open 12.19
Price To Book 3.48
Market Cap 393239954
Shares 31,358,848
Volume 126,946
Short Ratio
Av. Daily Volume 210,462

NewsSee all news

  1. Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
  2. Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
  3. Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript
  4. Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
  5. Forty Seven, Inc. to Host Earnings Call

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data to be presented at EHA June 15, 2019, 4:15pm.
5F9 + rituximab
Non-Hodgkin Lymphoma (NHL) - cancer
Phase 1b/2 data due 4Q 2019.
5F9 + cetuximab
Colorectal cancer
Phase 1b data to be presented at ASCO June 3, 2019 4:30pm CT.
5F9
Acute myeloid leukemia (AML)
Phase 1b data to be presented at ASCO June 3, 2019 4:30pm CT.
5F9 + Azacitidine
Acute myeloid leukemia (AML)
Phase 1 trial ongoing.
5F9
Solid tumors
Phase 1b data due 4Q 2019.
5F9 + Avelumab
Ovarian cancer

Latest News

  1. Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma at 24th Congress of the European Hematology Association
  2. Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
  3. Forty Seven Inc. (FTSV) Q1 2019 Earnings Call Transcript
  4. Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights
  5. Forty Seven, Inc. to Host Earnings Call
  6. Were Hedge Funds Right About Dumping Forty Seven, Inc. (FTSV)?
  7. Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
  8. Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin’s Lymphoma
  9. Top Ranked Momentum Stocks to Buy for April 25th
  10. Could Forty Seven, Inc.'s (NASDAQ:FTSV) Investor Composition Influence The Stock Price?
  11. Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  12. Forty Seven Inc. to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 28, 2019
  13. Forty Seven Inc. to Present at Oppenheimer 29th Annual Healthcare Conference
  14. Health Care Digest: Salesforce's DNA leads deeper into health, a defiant cancer startup and more
  15. Forty Seven Inc. to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
  16. Forty Seven Inc. to Host Key Opinion Leader Breakfast Symposium on FSI-174, anti-cKIT Antibody, on January 22, 2019
  17. Forty Seven Inc. Announces 2019 Strategic Priorities and Expected Milestones
  18. Here are the winners and losers from Bay Area's IPO class of 2018
  19. Should You Take Comfort From Insider Transactions At Forty Seven, Inc. (NASDAQ:FTSV)?